Physician profile
Thomas K Hamilton
NPI 1902800659
$1,486.42
in general payments reported to CMS, 2019-2025
20 companies · $33.40 in 2025
The $33.40 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $301 · 2021: $165 · 2022: $167 · 2023: $195 · 2024: $141 · 2025: $33.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $281.80 | 2019-2025 | Breztri |
| Pfizer INC. | $267.15 | 2019-2023 | |
| Novo Nordisk INC | $214.08 | 2019-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.86 | 2020-2024 | Jardiance |
| Lilly USA, LLC | $149.29 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Amgen INC. | $93.18 | 2019-2020 | |
| Abbott Laboratories | $33.33 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $30.42 | 2023-2024 | Contrave, Onzetra Xsail |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.07 | 2022 | |
| Merck Sharp & Dohme LLC | $28.24 | 2019 | |
| Glaxosmithkline, LLC. | $27.71 | 2019-2023 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $27.66 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.14 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.64 | 2023 | Quviviq |
| Mylan Specialty L.P. | $15.35 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $14.43 | 2022 | |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.20 | 2020 | |
| Eisai INC. | $12.18 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.